Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reflects a negative sentiment due to declining revenue, decreased gross margin, and reduced net income, all of which are concerning for investors. The increased R&D expenses, while potentially beneficial in the long term, contribute to the current financial strain. The absence of strategic initiatives or positive guidance further exacerbates the negative outlook. Additionally, the lack of clarity in management's responses during the Q&A session adds to investor uncertainty, likely leading to a negative stock price movement in the short term.
Key Financial Performance
Revenue Veru reported revenue of $12.5 million for Q2 2026, a decrease of 15% year-over-year. The decline was attributed to lower sales in the oncology segment due to increased competition.
Gross Margin The gross margin for Q2 2026 was 65%, down from 70% in the same period last year. The decrease was due to higher production costs and a shift in product mix.
Net Income Net income for Q2 2026 was $2.3 million, compared to $3.1 million in Q2 2025, representing a 25.8% decrease. This was primarily due to increased R&D expenses.
Research and Development Expenses R&D expenses increased by 30% year-over-year to $5 million in Q2 2026, driven by investments in new product development.
Operating Cash Flow Operating cash flow was $1.8 million for Q2 2026, a decline of 10% year-over-year, mainly due to higher operating expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Barnette Chief
CEO Michele
CFO Chief
Chairman President
Co Inc
Communications Chairman
Communications statement
Commute Executive
Conference event
Corporate Communications
Corporate Commute
Counsel Executive
Director Investor
Division EDT
Dr Vera
EDT lady
Executive Director
Fisch Executive
General Counsel
Gershell Oppenheimer
Greco CFO
Investor Relations
Leland Gershell
Michele Greco
Mr Veru
Officer Barnette
Officer Leland
President CEO
Relations Corporate
Samuel Fisch
Vera Inc
Veru Inc
gentleman Veru
VERU Transcript
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
Unknown5-13
The earnings call summary reflects a negative sentiment due to declining revenue, decreased gross margin, and reduced net income, all of which are concerning for investors. The increased R&D expenses, while potentially beneficial in the long term, contribute to the current financial strain. The absence of strategic initiatives or positive guidance further exacerbates the negative outlook. Additionally, the lack of clarity in management's responses during the Q&A session adds to investor uncertainty, likely leading to a negative stock price movement in the short term.
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Unknown2-11
The earnings call presents a mixed picture. While there are positive developments in clinical trials and financial improvements, significant risks and challenges remain. The regulatory hurdles for enobosarm, bone density concerns, and intense market competition could weigh on investor sentiment. The Q&A session did not reveal any new risks, but the lack of profitability and the need for clear market advantages are concerns. The financial position shows improved cash reserves, but sustainability is uncertain. These factors balance each other out, leading to a neutral sentiment rating.
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Positive12-17
The earnings call highlights several positive aspects: a significant reduction in net loss, gains from asset sales, and a promising new formulation of enobosarm with extended patent protection. While there are concerns about increased cash use and unclear management responses, the overall strategic direction, market potential, and regulatory flexibility provide a positive outlook, likely resulting in a 2% to 8% stock price increase.
Veru Inc. (VERU) Q3 2025 Earnings Call Transcript
Unknown8-12
The earnings call summary and Q&A indicate mixed signals. While the company shows progress in drug development and partnership discussions, financial health raises concerns due to insufficient cash for long-term operations and a significant net loss. The potential for new partnerships and an improved formulation could be positive, but financial constraints and the need for substantial capital for Phase III trials temper expectations. The market is likely to react cautiously, resulting in a neutral sentiment.
VERU Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
